ACTIVE HALF-LIFE: 12 hours
CLASSIFICATION: SARM
DOSAGE: 10mg/Pill
ACNE: NO
WATER RETENTION: No
HBR: No
HEPATOXITY: No
AROMATIZATION: NO
Certainly! Here’s a rewritten version of the text:
S23 is recognized as one of the most powerful and effective Selective Androgen Receptor Modulators (SARMs) currently available, with YK11 being its close alternative.
Formulated by modifying the chemical structure of a compound known as C-6, S23 is an advanced iteration of C-6, providing better bioavailability and binding affinity. With a remarkable bioavailability of up to 96%, its binding affinity is among the highest of any SARM, rivaling that of LGD-4033.
As a full agonist of the androgen receptor, S23, like LGD-4033, uniquely possesses this characteristic, which leads to its suppressive effects similar to steroids, influencing testosterone levels. Notably, S23 has been shown to cause infertility in rats in studies, underscoring its impressive potency.
S23 functions similarly to anabolic steroids while being selective in its action on androgen receptors in muscle tissue, minimizing effects on other areas such as the prostate that are commonly affected by steroids.
Function of S23:Advantages of S23:It’s recommended to start with a cautious dose of 5mg daily, gradually increasing based on individual tolerance, with a maximum of 15mg per day. Due to its 12-hour half-life, splitting the daily dose into morning and evening is preferable. Limit cycles to 8 weeks, and avoid prolonged use.
Dosage and Cycle Duration:S23 is unique among SARMs (potentially including YK11) in requiring PCT due to its strength. A suggested 4-week PCT with Clomid is recommended at the end of the cycle.
PCT for S23:While S23 offers considerable benefits, its limited research suggests the necessity for caution. Consideration of other well-researched SARMs is recommended before deciding on S23. Beginning with lower doses may help avoid the need for PCT. Always use S23 responsibly, being aware of its potential side effects and acknowledging its strength.
Final Thoughts: